A Prospective Randomized Controlled Trial of Morphine versus Oxycodone for Cancer Pain: Genetic Determinants of Response to Opioids. - RCT Morphine vs Oxycodone: Genetics Study

The Royal Marsden Hospital NHS Foundation Trust0 个研究点目标入组 0 人开始时间: 2005年7月7日最近更新: 2019年11月25日

适应症

试验速览

暂无简介。

•Inclusion Criteria
•Patients must have a clinical or histological diagnosis of cancer.
•Patients whose pain is not controlled on Step 2 analgesics (as defined by the WHO analgesic ladder) who clinically require a strong opioid.
•Patients must be over 18 years of age.
•Patients must be able to give written informed consent.
•Patients must be willing to undergo genetic screening
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Exclusion Criteria
•Patients with renal failure (1.5x ULN). These patients should be treated with alfentanil as per palliative care guidelines.
•Patients must not have been taking regular Step 3 analgesics in the last month.
•Patients requiring parenteral administration of opioids.
•Patients with predominantly neuropathic pain.
•Patients with predominantly incident pain
•Patients with a clearly defined history of intolerance to morphine or oxycodone.

发起方

The Royal Marsden Hospital NHS Foundation Trust